BSD Medical’s Fiscal Second Quarter Revenues Increase 106% to $1.7 Million
March 05 2014 - 3:14PM
Business Wire
Revenues for the First Half of Fiscal 2014 Increase 104% to
$3.0 million
Company to Report Full Second Quarter Financial Results and
Will Hold an Investment Community Conference Call on April
9
BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD)
(www.BSDMedical.com), a leading provider of medical systems that
treat cancer and benign diseases using heat therapy, today reported
revenues for the quarter ended February 28, 2014, of $1.7 million,
an increase of 106% compared with $819,000 for the comparable
quarter of the prior year. Revenues for the six months ended
February 28, 2014, were $3.0 million, an increase of 104% from $1.5
million for the six months of the prior year.
“BSD more than doubled revenues over the prior year comparable
periods due primarily to increased sales of our MicroThermX®
Microwave Ablation System,” said Harold Wolcott, President of BSD
Medical. "We believe these results show a growing recognition of
the role of the MicroThermX system in the treatment of cancer, as
well as the benefits of our strong relationship with Terumo Europe
NV. We have significantly increased the number of MicroThermX
systems in use and are beginning to see substantial growth in our
sales of disposable antennas. This is consistent with our long-term
strategy of delivering a high margin, profitable business with
recurring revenues.”
BSD Medical announced that it will report full financial results
for the second quarter of fiscal 2014 on Wednesday, April 9, 2014.
Management will hold a conference call that day at 2:00 p.m.
Eastern time/12:00 p.m. Mountain time to discuss financial results
and provide a business update.
Individuals may participate on the call by dialing 877-941-1466
in the U.S. or 480-629-9870 outside the U.S. and entering passcode
4673204. A telephone replay will be available until April 16, 2014,
by dialing 800-406-7325 in the U.S. or 303-590-3030 outside the
U.S. and entering conference ID 4673204. The conference call will
be available via webcast for 90 days by visiting the Investor
Relations section of the Company's website at
www.BSDMedical.com.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy delivered using focused microwave energy and radiofrequency
(RF). BSD’s product lines include ablation and hyperthermia
treatment systems. BSD’s microwave ablation system has been
developed as a stand-alone therapy to ablate and destroy soft
tissue. The Company has developed extensive intellectual property,
multiple products in the market, and well established distribution
in the United States, Europe and Asia. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors
with heat (hyperthermia) while increasing the effectiveness of
other therapies such as radiation therapy. Certain of the Company’s
products have received regulatory approvals in the United States,
Europe and China. For further information visit BSD Medical's
website at www.BSDMedical.com.
Forward-Looking Statements
Statements contained in this press release that are not
historical facts, including statements relating to our 2014 plans,
are forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. All forward-looking
statements are subject to risks and uncertainties detailed in the
Company's filings with the Securities and Exchange Commission,
including the market demand for our MicroThermX® products and the
regulatory requirements we face. These forward-looking statements
speak only as of the date on which such statements are made, and
the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date, except as
required by law.
BSD Medical CorporationWilliam Barth,
801-972-5555investor@bsdmc.comfax: 801-972-5930